March October: Company and Keyup Listener

march october: The Company also reported key clinical and corporate developments achieved during fiscal 2019, according to The Independent. Clinical and Corporate Developments included In March and October 2019, the Independent Data Monitoring Committee IDMC for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine Leukocyte Interleukin, Injection had an official review of the study data and recommended that the trial continue until the appropriate number of events has occurred. Search first keyup' ; ; listener ; ;No matching results for ''Tip Try a valid symbol or a specific company name for relevant results Cancel Sign in Mailif window.performance window.performance.mark && && Finance Videos News Techif window.performance window.performance.mark && && U.S. Markets open in 4 hrs 3 minsS&P window.performance window.performance.mark && && window.performance window.performance.mark && && window.performance window.performance.mark && && window.performance window.performance.mark && && window.performance window.performance.mark && && window.performance window.performance.mark && && window.performance window.performance.mark && && Reports Fiscal 2019 Financial Results and Clinical & Corporate Developmentsif window.performance window.performance.mark && && Wire December 16, 2019if window.performance window.performance.mark && && window.performance window.performance.mark && && window.performance window.performance.mark && && window.performance window.performance.mark && && Corporation NYSE American CVM reported financial results for the fiscal year ended September 30, 2019. The data from all 928 enrolled patients were provided to the IDMC by the clinical research organization CRO responsible for data management of this Phase 3 study. CEL-SCI is now awaiting final study results in its Phase 3 head and neck cancer trial. At the most recent IDMC meeting in October 2019 the IDMC reviewed progression free and overall survival and limited demographic and safety data available for the aforementioned protocol. (news.financializer.com). As reported in the news.